0001628945-23-000024.txt : 20230301 0001628945-23-000024.hdr.sgml : 20230301 20230301161014 ACCESSION NUMBER: 0001628945-23-000024 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230227 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230301 DATE AS OF CHANGE: 20230301 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cue Health Inc. CENTRAL INDEX KEY: 0001628945 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 271562193 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40824 FILM NUMBER: 23693560 BUSINESS ADDRESS: STREET 1: 4980 CARROLL CANYON ROAD STREET 2: SUITE 100 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 412-8151 MAIL ADDRESS: STREET 1: 4980 CARROLL CANYON ROAD STREET 2: SUITE 100 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: Cue Inc. DATE OF NAME CHANGE: 20141223 FORMER COMPANY: FORMER CONFORMED NAME: Cue, Inc. DATE OF NAME CHANGE: 20141222 8-K 1 hlth-20230227.htm 8-K hlth-20230227
0001628945FALSE00016289452022-03-292022-03-29

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
Date of Report (Date of earliest event reported): February 27, 2023
 
CUE HEALTH INC.

(Exact name of Registrant, as specified in its charter)
Delaware
001-40590
27-1562193
(State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification Number)

Mailing address:
4980 Carroll Canyon Rd.
Suite 100
San Diego, CA 92121
(Address of principal executive
offices)

Registrant's telephone number, including area code: (858) 412-8151

Former name or address, if changed since last report: Not Applicable.

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.00001 per share
 HLTH 
Nasdaq Global Stock Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Chief Financial Officer Transition

On February 27, 2023, John Gallagher, Chief Financial Officer of Cue Health Inc. (the “Company”) tendered his resignation as Chief Financial Officer to be effective as of March 16, 2023 (the “Effective Date”). The Company is appreciative of the service of Mr. Gallagher and his resignation is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Mr. Gallagher’s existing compensation arrangements will remain in place during his remaining period of employment.

On February 28, 2023, the Board of Directors (the “Board”) approved the appointment of Mr. Aasim Javed as the Chief Financial Officer and Principal Financial Officer of the Company, upon the Effective Date.

Mr. Javed, 39, has served as the Company’s Vice President of Finance and Treasurer since April 2021. Prior to joining the Company, Mr. Javed served in various roles at Becton, Dickinson and Company, a medical technology company, from November 2015 to April 2021, including as Senior Director of Financial Planning and Analysis and Senior Director of Corporate Treasury. Mr. Javed has also been Associate Director of North America Budget and Business Planning at the Kraft Heinz Company, and Manager of Treasury Operations at General Motors. Mr. Javed holds a Bachelor of Commerce degree in Finance and Accounting from McGill University and a Master of Business Administration degree from Harvard Business School.

Appointment of Certain Officers

In addition, on February 28, 2023, the Board also approved the appointment, effective immediately, of Randall Pollard as Principal Accounting Officer of the Company.

Mr. Pollard, 51, has served as the Company’s Chief Accounting Officer and Controller since April 2022. Prior to joining the Company, Mr. Pollard served as Senior Vice President of Finance and Chief Accounting Officer at Covis Pharmaceuticals, Inc. from November 2020 to April 2022. He previously served in various roles at Akorn, Inc. from April 2015 to November 2020, including as Senior Vice President of Finance and Chief Accounting Officer, Interim Chief Financial Officer and Corporate Controller. Mr. Pollard holds a Bachelor of Science degree in Accounting from Penn State University and a Master of Business Administration degree from Fairleigh Dickinson University.

There are no arrangements or understandings between Mr. Javed and any other person pursuant to which he was appointed Chief Financial Officer and Principal Financial Officer of the Company, and there are no arrangements or understandings between Mr. Pollard and any other person pursuant to which he was appointed Principal Accounting Officer of the Company. There are no family relationships between Mr. Javed or Mr. Pollard and any director or other executive officer of the Company, or any person nominated or chosen by the Company to become a director or executive officer. Since the beginning of the Company’s last fiscal year, the Company has not engaged in any transaction in which either Mr. Javed or Mr. Pollard has any direct or indirect material interest within the meaning of Item 404(a) of Regulation S-K.

The Company intends to file an amendment to this Form 8-K following determination of any material compensation arrangements in connection with Mr. Javed’s service as Chief Financial Officer and Principal Financial Officer of the Company and Mr. Pollard’s service as Principal Accounting Officer of the Company.

Item 9.01    Financial Statements and Exhibits.
 
Exhibit No.Description
104Cover page interactive data file
2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Cue Health Inc.
 Date: March 1, 2023By:/s/ Ayub Khattak
 Name:Ayub Khattak
 Title:Chief Executive Officer

3
 EX-101.SCH 2 hlth-20230227.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 hlth-20230227_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Pre-commencement Tender Offer Pre-commencement Tender Offer Amendment Flag Amendment Flag Entity Address, State or Province Entity Address, State or Province Entity Ex Transition Period Entity Ex Transition Period Entity Tax Identification Number Entity Tax Identification Number Title of 12(b) Security Title of 12(b) Security Entity File Number Entity File Number Written Communications Written Communications Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Trading Symbol Trading Symbol Document Period End Date Document Period End Date Soliciting Material Soliciting Material Document Type Document Type City Area Code City Area Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name Entity Address, Address Line Two Entity Address, Address Line Two Local Phone Number Local Phone Number Entity Address, City or Town Entity Address, City or Town Cover [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Security Exchange Name Security Exchange Name EX-101.PRE 4 hlth-20230227_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover
Mar. 29, 2022
Cover [Abstract]  
Document Type 8-K
Document Period End Date Feb. 27, 2023
Entity Registrant Name CUE HEALTH INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-40590
Entity Tax Identification Number 27-1562193
Entity Address, Address Line One 4980 Carroll Canyon Rd.
Entity Address, Address Line Two Suite 100
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code 858
Local Phone Number 412-8151
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.00001 per share
Trading Symbol HLTH
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001628945
Amendment Flag false
XML 6 hlth-20230227_htm.xml IDEA: XBRL DOCUMENT 0001628945 2022-03-29 2022-03-29 0001628945 false 8-K 2023-02-27 CUE HEALTH INC. DE 001-40590 27-1562193 4980 Carroll Canyon Rd. Suite 100 San Diego CA 92121 858 412-8151 false false false false Common Stock, par value $0.00001 per share HLTH NASDAQ true false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 24 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://cuehealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports hlth-20230227.htm hlth-20230227.xsd hlth-20230227_lab.xml hlth-20230227_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "hlth-20230227.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "hlth-20230227.htm" ] }, "labelLink": { "local": [ "hlth-20230227_lab.xml" ] }, "presentationLink": { "local": [ "hlth-20230227_pre.xml" ] }, "schema": { "local": [ "hlth-20230227.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "hlth", "nsuri": "http://cuehealth.com/20230227", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hlth-20230227.htm", "contextRef": "i237a36645cf14d9782a864756c9fe4d9_D20220329-20220329", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://cuehealth.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hlth-20230227.htm", "contextRef": "i237a36645cf14d9782a864756c9fe4d9_D20220329-20220329", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://cuehealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://cuehealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://cuehealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://cuehealth.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://cuehealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://cuehealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://cuehealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://cuehealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://cuehealth.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://cuehealth.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://cuehealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://cuehealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://cuehealth.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://cuehealth.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://cuehealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://cuehealth.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://cuehealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://cuehealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://cuehealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://cuehealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://cuehealth.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://cuehealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://cuehealth.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://cuehealth.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 13 0001628945-23-000024-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628945-23-000024-xbrl.zip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end